Aurora Cannabis Discovers Powdery Mildew Resistant Strains

TL;DR

Aurora Cannabis found new mildew-resistant strains, potentially boosting their crop yields and cutting costs.

AI Summary

Aurora Cannabis Inc. announced on March 20, 2025, a significant breakthrough with the discovery of new powdery mildew resistant cultivars. This discovery is expected to reduce crop losses and improve operational efficiency for the company.

Why It Matters

This discovery could significantly reduce crop losses due to powdery mildew, a common issue in cannabis cultivation, leading to improved yields and profitability for Aurora Cannabis.

Risk Assessment

Risk Level: low — The filing is an informational update (6-K) announcing a discovery, not a financial event with immediate market-moving risk.

Key Players & Entities

• Aurora Cannabis Inc. (company) — Registrant and subject of the news release
• Miguel Martin (person) — Chief Executive Officer of Aurora Cannabis Inc.
• March 20, 2025 (date) — Date of the news release and filing

FAQ

From the Filing

0001279569-25-000280.txt : 20250320 0001279569-25-000280.hdr.sgml : 20250320 20250320092709 ACCESSION NUMBER: 0001279569-25-000280 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250320 FILED AS OF DATE: 20250320 DATE AS OF CHANGE: 20250320 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 25754688 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated March 20, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: March 20, 2025 EX-99.1 2 ex991.htm NEWS RELEASE DATED MARCH 20, 2025 Exhibit 99.1 Aurora Cannabis Announces Breakthrough Discovery of Powdery Mildew Resistant Cultivars NASDAQ | TSX: ACB Groundbreaking research at Aurora Coast, Aurora's world-class research and development facility, sets new standard in cannabis science EDMONTON, AB, March 20, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, is pleased to announce the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year. "This discovery offers a critical solution to a pressing challenge in the cannabis industry worldwide. At Aurora Coast, our state-of-the-art research and development facility, we continuously search for ways to add value to our proprietary cannabis cultivars, and this discovery will lead to new means of managing disease in cannabis production. This success story underscores the impact of our investment in scientific excellence, a commitment that sets Aurora apart from our competitors," says Lana Culley, Vice President of Innovation and International Operations at Aurora. In the peer reviewed research lead by Jose Celedon, Principal Scientist of Breeding and Genetics at Aurora, in collaboration with researchers at The University of British Columbia, it is noted that, "breeding genetic resistance to economically important crop diseases is the most sustainable strategy for disease management and enhancing agricultural and horticultural productivity, particularly where the application of synthetic pesticides is prohibited" (Seifi, et al.) 1 . The discovery of PM2 will further the company's mission to enhance the biosecurity of production facilities, reduce production costs, and improve product quality. As a global medical cannabis company enabled by science,